Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial.
Turner K, Kim DW, Gonzalez BD, Gore LR, Gurd E, Milano J, Riccardi D, Byrne M, Al-Jumayli M, de Castria TB, Laber DA, Hoffe S, Costello J, Robinson E, Chadha JS, Rajasekhara S, Hume E, Hagen R, Nguyen OT, Nardella N, Parker N, Carson TL, Tabriz AA, Hodul P. Turner K, et al. Among authors: de castria tb. Contemp Clin Trials Commun. 2024 Feb 23;38:101271. doi: 10.1016/j.conctc.2024.101271. eCollection 2024 Apr. Contemp Clin Trials Commun. 2024. PMID: 38440777 Free PMC article.
Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma.
Capareli F, Costa F, Tuszynski JA, Sousa MC, Setogute YC, Lima PD, Carvalho L, Santos E, Gumz BP, Sabbaga J, de Castria TB, Jardim DL, Freitas D, Horvat N, Bezerra ROF, Testagrossa L, Costa T, Zanesco T, Iemma AF, Abou-Alfa GK. Capareli F, et al. Among authors: de castria tb. Cancer Med. 2023 Jun;12(11):12402-12412. doi: 10.1002/cam4.5944. Epub 2023 May 15. Cancer Med. 2023. PMID: 37184216 Free PMC article. Clinical Trial.
A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma.
Yan T, Huang C, Peng C, Duan X, Ji D, Duan Y, Zhang W, Zhao H, Gao K, Yang X, Zhang L, Cheng J, de Castria TB, Pocha C, Tsilimigras DI, Wu T, Su G, Li Y, Yu L, Lu Y. Yan T, et al. Among authors: de castria tb. Ann Transl Med. 2023 Jan 31;11(2):109. doi: 10.21037/atm-22-6614. Ann Transl Med. 2023. PMID: 36819518 Free PMC article.
The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma.
Huang E, Ma T, Zhou J, Ma N, Yang W, Liu C, Hou Z, Chen S, de Castria TB, Zeng B, Zong Z, Zhou T. Huang E, et al. Among authors: de castria tb. Ann Transl Med. 2022 Jul;10(14):766. doi: 10.21037/atm-22-3348. Ann Transl Med. 2022. PMID: 35965795 Free PMC article.
Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report.
de Castria TB, Tang L, Queiroz MM, Awni BM, Paroder V, Shamseddine A, Bariani GM, Mukherji D, Matar CF, Fernandes GDS, El-Olayan A, Sabatin F, Elias R, Gupta R, Janjigian YY, Abou-Alfa GK. de Castria TB, et al. J Gastrointest Oncol. 2021 Dec;12(6):3123-3132. doi: 10.21037/jgo-21-287. J Gastrointest Oncol. 2021. PMID: 35070435 Free PMC article.
27 results